Hepatitis B; Prophylaxis

Recombinant hepatitis B vaccine is a non-infectious subunit viral vaccine. The vaccine is derived from hepatitis B surface antigen (HBsAg) produced through recombinant DNA techniques from yeast cells, Saccharomyces cerevisiae. The portion of the hepatitis B gene which codes for HBsAg is cloned into yeast which is then cultured to produce hepatitis B antigen

Severe allergic reaction after a previous dose of any hepatitis B-containing vaccine or to any vaccine component, including yeast

C(FDA) B2(ADEC)

Compatible with breastfeeding.(WHO)
Infant risk is minimal.(MDX)

The most common adverse effects reported with both products included injection site reactions (>10%).(UTD)

Primary immunization: IM:
Immunocompetent adults: 1 mL/dose (adult formulation) for 3 total doses administered at 0, 1, and 6 months.
Adults with immunocompromising conditions:
Engerix-B 20 mcg/mL: Administer 2 mL per dose at 0, 1, 2, and 6 months(UTD)

Primary immunization: IM
0.5 mL/dose (pediatric/adolescent formulation) for 3 total doses administered at 0, 1 and 6 months.

Dialysis patients:Administer 2 mL per dose at 0, 1, 2, and 6 months.(UTD)

Hepatitis B vaccine should be stored at 2 to 8 degrees Celsius.DO NOT freeze.